Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

27-plex Tandem Mass Tag Mass Spectrometry for Profiling Brain Proteome in Alzheimer's Disease

ABSTRACT: Systematically optimized the protocol for the newly developed 16-plex TMT Reported a novel 27-plex method to enhance the multiplexity for large-scale proteomic profiling, by combining two sets of distinct isobaric tags (11-plex and 16-plex TMT) based on their disparate mass shifts on modified peptides.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Brain, Cerebral Cortex

DISEASE(S): Alzheimer's Disease

SUBMITTER: Zhen Wang

LAB HEAD: Junmin Peng

PROVIDER: PXD025261 | Pride | 2021-04-09

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Publications

27-Plex Tandem Mass Tag Mass Spectrometry for Profiling Brain Proteome in Alzheimer's Disease.

Wang Zhen Z Yu Kaiwen K Tan Haiyan H Wu Zhiping Z Cho Ji-Hoon JH Han Xian X Sun Huan H Beach Thomas G TG Peng Junmin J

Analytical chemistry 20200507 10

Multiplexed isobaric labeling methods, such as tandem mass tags (TMT), remarkably improve the throughput of quantitative mass spectrometry. Here, we present a 27-plex TMT method coupled with two-dimensional liquid chromatography (LC/LC) for extensive peptide fractionation and high-resolution tandem mass spectrometry (MS/MS) for peptide quantification and then apply the method to profile the complex human brain proteome of Alzheimer's disease (AD). The 27-plex method combines multiplexed capaciti ...[more]

PMID: 32343560

Similar Datasets

29-Plex Tandem Mass Tag Mass Spectrometry Enabling Accurate Quantification by Interference Correction

Project description:Tandem mass tag (TMT) mass spectrometry is a mainstream isobaric chemical labeling strategy for profiling proteomes. Here we present a 29-plex TMT method to combine the 11-plex and 18-plex labeling strategies. The 29-plex method was examined with a pooled sample composed of 1x, 3x and 10x E. coli peptides with 100x human background peptides, which generated two E. coli datasets (TMT11 and TMT18), displaying the distorted ratios of 1.0:1.7:4.2 and 1.0:1.8:4.9, respectively. This ratio compression from the expected 1:3:10 ratios was caused by co-isolated TMT-labeled ions (i.e., noise). Interestingly, the mixture of two TMT sets produced MS/MS spectra with unique features for the noise detection: (i) in TMT11-labeled spectra, TMT18-specific reporter ions (e.g., 135N) were shown as the noise; (ii) in TMT18-labeled spectra, the TMT11/TMT18-shared reporter ions (e.g., 131C) typically exhibited higher intensities than TMT18-specific reporter ions, due to contaminated TMT11-labeled ions in these shared channels. We further estimated the noise levels contributed by both TMT11- and TMT18-labeled peptides, and corrected reporter ion intensities in every spectrum. Finally, the anticipated 1:3:10 ratios were largely restored. This strategy was also validated using another 29-plex sample with 1:5 ratios. Thus the 29-plex method expands the TMT throughput and enhances the quantitative accuracy.

2023-03-10 | PXD033865 | Pride

Deep Multilayer Tissue Proteomics Identifies Molecular Networks in Alzheimer’s Disease Progression, human data

Project description:The molecular networks underlying Alzheimer’s disease (AD) are not well-defined. We present temporal profiling of >14,000 proteins and >34,000 phosphosites at the asymptomatic and symptomatic stages of AD, deep proteomics analysis of transgenic mouse models.

2019-11-11 | PXD007985 | Pride

A Tribrid Hyperplexing approach for Large-scale Quantitative Proteomic Analysis

Project description:Isobaric labeling has emerged as an indispensable quantitative proteomic approach for its unprecedented multiplexing capacity in a single analysis. Currently, different hyperplexing approaches have been developed to meet the need for increasing sample numbers in large-scale cohort analysis. In this report, we present a tribrid hyperplexing approach by the combinational use of three types of isobaric reagents, a novel isobaric tag 16-plex (IBT16) reagent, and the widely used TMT (TMT11) and TMTpro (TMT18) reagents. After the determination of the labeling efficiency and the optimization testing conditions, we systematically evaluated the identification and quantification performance of the three labeling methods in both independent and combinatorial means using the mixtures of E. coli and HeLa peptides with different ratios. Our results reveal that the three reagents are quite similar in all testing aspects although with some differences, and the combination use of three reagents to expand the multiplexing capacity is feasible. Furthermore, we provide practical recommendations for the choice of isobaric reagent combinations according to different plexes.

2023-03-17 | PXD037498 | Pride

Deep undepleted human serum proteome profiling toward biomarker discovery for Alzheimer’s disease

Project description:Alzheimer's disease (AD) is a neurodegenerative disease, the most common cause of dementia in elderly persons. Accumulation of amyloid plaques in the brain is a characteristic of AD. The requirements for a biomarker include the ability to measure a pathologic process, predict outcome, distinguish disease or measure a pharmacological response to a drug treatment or therapeutic intervention. However, there are no reliable blood based biomarkers for AD. Serum-based protein measurement is a routine practice for biomarkers in human disease, but comprehensive profiling of serum proteome is often masked by the twenty most abundant proteins and impacted by large dynamic range. The commonly used depletion method can alleviate the challenge but introduce additional experimental variation. Here we present a deep analysis of un-depleted human serum proteome by combining 11-plex TMT labeling, exhaustive 2D liquid chromatography fractionation, and high resolution tandem mass spectrometry. This platform is capable of identifying 4,500 protein components, covering 6 orders of dynamic range, representing one of the deepest serum proteome datasets. Finally, a subset of proteins, show statistically significant difference between AD and control samples, which may serve as biomarker candidates.

2019-04-23 | PXD011482 | Pride

Ultra Deep Mouse cerebrospinal fluid (CSF) profiling in Alzheimer’s disease

Project description:Alzheimer's disease (AD) is a neurodegenerative disease, the most common cause of dementia in elderly persons. Accumulation of amyloid plaques in the brain is a characteristic of AD. The requirements for a biomarker include the ability to measure a pathologic process, predict outcome, distinguish disease or measure a pharmacological response to a drug treatment or therapeutic intervention. However, there are no reliable blood based biomarkers for AD. CSF-based protein measurement can be used as a practice for biomarkers in human disease, but comprehensive profiling of Mouse CSF proteome is often masked by the twenty most abundant proteins and impacted by large dynamic range. The commonly used depletion method can alleviate the challenge but introduce additional experimental variation. Here we present a deep analysis of un-depleted CSF proteome by combining 11-plex TMT labeling, exhaustive 2D liquid chromatography fractionation, and high resolution tandem mass spectrometry. This platform is capable of identifying 1056 protein components, covering 6 orders of dynamic range, representing one of the proteome datasets. Finally, a subset of proteins, show statistically significant difference between AD and control samples, which may serve as biomarker candidates for the AD when further correlation can be drawn from the human proteome.

2021-09-09 | PXD018658 | Pride

BALF exosomes - Pulmonary Sarcoidosis is Associated With Exosomal Vitamin D-Binding Protein and Inflammatory Molecules

Project description:Using 8-plex iTRAQ labelling exosmes isolated from bronchial lavage (BALF) were analyzed by LC-MS/MS. The measurements compared control subjects with sarcoidosis patients (15 in all) ; five with löfgrens syndrome and 10 with regular sacroidosis

2016-09-27 | PXD001808 | Pride

TMT analysis of MOLM-13 cells treated with series 3 CK1a degraders

Project description:Targeted Protein Degradation (TPD) encompasses two approaches that generate small molecules with similar proteasome-dependent mechanisms of action: Proteolysis-Targeting Chimeras (PROTACs) and Molecular Glues (MGs). Our goal is to develop novel MG approaches that exploit the E3 ubiquitin ligase Cereblon (CRBN) to degrade key oncogenic drivers in the leading causes of childhood cancer death: acute myeloid leukemia (AML). This project will identify new vulnerabilities and compounds that degrade hitherto undruggable transcription factors in high-risk acute leukemia (AL) and medulloblastoma (MB). Based on our preliminary data, we hypothesize that these compounds target AML cells via CK1a degradation. Our aims are to understand the mechanism by which compounds SJ001041330, SJ001043149, and SJ001043301 target AML cells using TMT proteomic approach and confirm CK1a degradation by these compounds leading to AML cell death.

2023-12-01 | PXD045230 | Pride

TMT analysis of MOLM-13 cells treated with SJ001007095

Project description:Targeted Protein Degradation (TPD) encompasses two approaches that generate small molecules with similar proteasome-dependent mechanisms of action: Proteolysis-Targeting Chimeras (PROTACs) and Molecular Glues (MGs). Our goal is to develop novel MG approaches that exploit the E3 ubiquitin ligase Cereblon (CRBN) to degrade key oncogenic drivers in the leading causes of childhood cancer death: acute myeloid leukemia (AML). This project will identify new vulnerabilities and compounds that degrade hitherto undruggable transcription factors in high-risk acute leukemia (AL) and medulloblastoma (MB). Based on our preliminary data, we hypothesize that compound SJ001007095 targets AML cells independent of GSPT1 degradation. Our aims are to understand the mechanism by which compound SJ001007095 targets AML cells using TMT proteomic approach and identify proteins targeted by the compound SJ001007095 leading to their degradation and consequently AML cell death.

2023-12-01 | PXD045170 | Pride

Proteome profiling of MOLM-13 cells treated with proposed CK1α degraders

Project description:Targeted Protein Degradation (TPD) encompasses two approaches that generate small molecules with similar proteasome-dependent mechanisms of action: Proteolysis-Targeting Chimeras (PROTACs) and Molecular Glues (MGs). Our goal is to develop novel MG approaches that exploit the E3 ubiquitin ligase Cereblon (CRBN) to degrade key oncogenic drivers in the leading causes of childhood cancer death: acute myeloid leukemia (AML). This project will identify new vulnerabilities and compounds that degrade hitherto undruggable transcription factors in high-risk acute leukemia (AL) and medulloblastoma (MB). Based on our preliminary data, we hypothesize that each of these compounds (SJ001010039, SJ001010040, SJ001010041, SJ001010047, SJ001010050) degrades CK1α in this cell line and may degrade other proteins. Our aims are to confirm that CK1α is degraded by treatment with each of these compounds and to identify any additional proteins that are targeted for degradation by these compounds.

2023-12-01 | PXD045228 | Pride

Thermal stability variation during transtion to pluripotency

Project description:To investigate functional differences between pluripotent stem cells and somatic cells, we measured protein thermal stability and expression after transitions between cell types using allogenic cell lines. To this purpose, we reprogrammed hFF into human iPSCs and initiated undirected differentiation through formation of EBs during 21 days. We also included human embryonic stem cells (ESC) in order to validate our approach and colon cancer cell line RKO.

2021-10-05 | PXD018453 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data